Remifentanil 5mg/ml Injection for Anesthesia and Pain

Remifentanil 5mg/ml is an ultra-short-acting synthetic opioid analgesic used primarily in anesthesia and monitored anesthesia care. As a potent mu-opioid receptor agonist with rapid onset and offset, remifentanil provides intense analgesia during surgical procedures with minimal residual effects post-procedure.

Clinical Applications and Medical Uses

Remifentanil 5mg/ml injection serves critical functions in medical settings:

• General anesthesia induction and maintenance - Provides profound analgesia during intubation, incision, and surgical manipulation
• Monitored anesthesia care (MAC) - Enables conscious sedation for minor procedures with rapid arousal
• Post-operative pain control - Immediate post-surgical analgesia in recovery settings
• Obstetric anesthesia - Labor analgesia with minimal neonatal depression due to rapid metabolism
• Cardiac surgery - Stable hemodynamics with intense analgesia during bypass procedures
• Neurosurgical procedures - Allows rapid neurological assessment due to ultra-short duration

The 5mg/ml concentration provides flexibility in dosing for varying procedural durations from brief outpatient procedures to lengthy complex surgeries.

Unique Pharmacological Properties

Remifentanil differs fundamentally from other opioids due to its metabolism by non-specific tissue and plasma esterases rather than hepatic enzymes. This creates predictable, rapid clearance regardless of hepatic or renal function.

Pharmacokinetic characteristics:

• Onset: 1-2 minutes (faster than fentanyl)
• Peak effect: 3-5 minutes
• Duration: 5-10 minutes (context-sensitive half-life of 3-4 minutes)
• Elimination half-life: 3-10 minutes (constant, regardless of infusion duration)
• Context-sensitive half-time: 3-4 minutes even after 4-hour infusions

Unlike morphine, fentanyl, or sufentanil, remifentanil does not accumulate with prolonged infusions, making it ideal for lengthy procedures requiring rapid emergence.

Potency and Comparative Analysis

Remifentanil bridges the gap between the ultra-long duration of sufentanil and the intermediate duration of alfentanil, offering unique pharmacodynamic advantages for specific clinical scenarios.

Dosage Guidelines and Administration

Remifentanil requires intravenous administration by trained anesthesia professionals in monitored settings with resuscitation equipment available.

Typical dosing protocols:

• Induction bolus: 0.5-1 mcg/kg over 30-60 seconds
• Continuous infusion: 0.05-0.4 mcg/kg/min titrated to effect
• Supplemental boluses: 0.25-0.5 mcg/kg for breakthrough stimuli
• Conscious sedation: 0.025-0.1 mcg/kg/min infusion

Significant dose reduction (up to 75% decrease) required when combined with propofol, benzodiazepines, or volatile anesthetics due to synergistic respiratory depression.

Safety Profile and Contraindications

Absolute contraindications:

• Known hypersensitivity to remifentanil or fentanyl analogs
• Intrathecal or epidural administration (formulation not suitable)
• Epidural or intrathecal injection (specific formulation contraindications)

Critical warnings:

• Profound respiratory depression requiring ventilatory support
• Chest wall rigidity at higher doses (treatable with neuromuscular blockers)
• Bradycardia, especially with vagal stimuli
• Hypotension from sympathetic blockade
• NOT for intrathecal, epidural, or intramuscular use

Side Effects and Adverse Reactions

Common effects:

• Respiratory depression (universal at therapeutic doses)
• Bradycardia and hypotension
• Nausea and vomiting (especially post-procedure)
• Pruritus without rash
• Shivering and thermal dysregulation

Serious adverse reactions:

• Apnea and respiratory arrest
• Severe bradycardia requiring atropine or pacing
• Chest wall rigidity impairing ventilation
• Allergic reactions including anaphylaxis

Drug Interactions

Synergistic respiratory depression (profound risk):

• Propofol, thiopental, etomidate
• Benzodiazepines (midazolam, diazepam, lorazepam)
• Volatile anesthetics (isoflurane, sevoflurane, desflurane)
• Neuromuscular blocking agents
• Other opioids (morphine, fentanyl, hydromorphone)

Reduced metabolism potential:

• Esterase inhibitors may prolong duration
• Pseudocholinesterase deficiency theoretically relevant but rarely clinically significant

Post-Procedure Considerations

Unlike other opioids, remifentanil does not cause prolonged respiratory depression after discontinuation. However, rapid offset means alternative analgesia must be established before emergence:

• Transition to longer-acting opioids (fentanyl, morphine, hydromorphone) 20-30 minutes before procedure end
• Regional anesthesia techniques for post-operative pain
• Non-opioid multimodal analgesia (acetaminophen, NSAIDs, gabapentinoids)

Ordering Remifentanil from Our Pharmacy

We supply pharmaceutical-grade remifentanil 5mg/ml injection for legitimate medical and research applications:

• Authentic pharmaceutical products with cold chain shipping
• Certificate of analysis and lot traceability
• Secure, discreet packaging
• Expedited shipping options available
• 24/7 customer support: +17473176527 (call, text, WhatsApp)
• Flexible payment options: Credit cards, secure card payments, card, PayPal, Apple Pay, Google Pay

Professional medical license or research institution documentation required for all purchases of this Schedule II controlled substance.

Alternative Ultra-Short Opioids

Depending on procedural requirements, consider:

• Alfentanil - Intermediate duration (10-20 min) for medium-length procedures
• Sufentanil - Higher potency (500-1000x morphine) for cardiac procedures
• Fentanyl - Standard ultra-potent opioid for general use
• Opana (oxymorphone) - Long-acting for post-operative pain